Please ensure Javascript is enabled for purposes of website accessibility
Contact us Contact Us
EN
Home > Featured Products > Oncology Research > Melanoma

Melanoma Research Reagents

Melanoma has become the paradigm for immune checkpoint therapy, with BRAF/MEK-targeted and PD-1/CTLA-4-based combination regimens transforming patient outcomes. abinScience provides antibodies, recombinant proteins, and assay kits spanning BRAF, MAPK pathway, melanocyte-lineage diagnostic markers (S100, gp100/PMEL, Melan-A), and the full spectrum of immune checkpoint targets. RUO

Key Biomarkers & Targets

BRAF
V600E/V600K
BRAF V600 mutations present in ~50% of cutaneous melanomas. Target of vemurafenib and dabrafenib. 79 antibodies for mutation-associated signaling studies.
Antibodies
PD-1 / PD-L1
CD279 / CD274
First cancer type where anti-PD-1 (nivolumab, pembrolizumab) achieved durable responses. 260+ combined antibodies, proteins, and biosimilars.
Antibodies • Proteins • Biosimilars
CTLA-4
CD152
Ipilimumab (anti-CTLA-4) was the first checkpoint inhibitor approved in melanoma. 144 products for combination immunotherapy studies.
Antibodies • Proteins • Biosimilars
LAG-3 / TIGIT / TIM-3
Next-Gen Checkpoints
Emerging immune checkpoints under active clinical investigation in melanoma (relatlimab + nivolumab). 125+ combined products.
Antibodies • Proteins • Biosimilars
gp100 / PMEL
Melanocyte Antigen
Melanoma-associated antigen; target of tebentafusp (bispecific gp100×CD3). 20 antibodies for tumor antigen detection and T-cell assay development.
Antibodies • Biosimilars
S100
S100B / S100A4
Classic IHC diagnostic marker for melanocytic lesions. Serum S100B used for monitoring metastatic disease progression. 41 products.
Antibodies • Proteins

Why Researchers Choose abinScience for Melanoma

MAPK Pathway Depth BRAF → MEK → ERK signaling cascade covered end-to-end. Antibodies for studying resistance mechanisms to BRAF/MEK inhibitor combinations.
Complete Checkpoint Portfolio PD-1, PD-L1, CTLA-4, LAG-3, TIGIT, TIM-3, IDO1 — the most comprehensive immune checkpoint reagent set for melanoma immuno-oncology research.
Melanocyte-Lineage Diagnostics S100, gp100/PMEL, Melan-A/MART-1, MITF, SOX10, tyrosinase — a full panel for melanoma diagnosis and differentiation from other malignancies.
Bispecific & TCR-T Reference gp100–peptide/HLA-A2 complex antibodies and tebentafusp biosimilar for next-generation bispecific and TCR-based therapy development.
Original Manufacturer Pricing Direct-from-manufacturer pricing with no distributor markup. Bulk and custom conjugation options available.

Common Research Applications

  1. BRAF/MEK resistance profiling: Use BRAF, MEK1/2, and phospho-ERK antibodies (WB, IHC) to characterize acquired resistance mechanisms in melanoma cell lines and PDX models.
  2. Immune checkpoint combination screening: Evaluate PD-1 + CTLA-4, PD-1 + LAG-3, and other dual-blockade strategies with recombinant checkpoint proteins in reporter cell-based assays.
  3. Melanoma vs. non-melanoma differential diagnosis: Apply our S100, SOX10, gp100, and Melan-A antibodies in IHC panels to distinguish melanoma from poorly differentiated carcinoma and other spindle-cell tumors.
  4. Neoantigen & TCR-T development: Use our gp100/HLA-A2 complex reagents and IDO1 proteins for T-cell activation assays, antigen-specific killing, and tumor immune evasion studies.

Documents & QC Data

Download product datasheets, validation images (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

FAQs

Do you carry BRAF V600E mutation-specific antibodies?

Our anti-BRAF antibodies detect total BRAF protein. For V600E-specific detection, we recommend combining our BRAF antibodies (WB) with mutation-specific recombinant proteins as positive controls in your assay.

Which checkpoint antibodies are best for melanoma TIL analysis?

For tumor-infiltrating lymphocyte characterization, we recommend our anti-PD-1, CTLA-4, LAG-3, TIGIT, and TIM-3 antibodies. These are available as unconjugated or can be custom-conjugated for flow cytometry panels.

What diagnostic IHC panel do you recommend for melanoma?

A standard melanoma IHC panel includes S100 (high sensitivity), SOX10 (nuclear marker), Melan-A/MART-1 (cytoplasmic), and HMB45/gp100 (specific for melanosomes). We offer antibodies for all four markers.

Do you have tebentafusp-related reagents?

Yes — we offer a research-grade tebentafusp biosimilar and anti-gp100/HLA-A2 complex antibodies for binding characterization, competitive assays, and T-cell redirection studies.

Can I get custom antibodies for novel melanoma neoantigens?

Yes — our parent company AtaGenix provides custom antibody development from immunogen design through monoclonal antibody production, including peptide-MHC complex-targeting antibodies for immuno-oncology.

739 product results for "Melanoma"

Options+
Options
Confirm
  • Product types
    0 selected
    Biosimilars (1)
    Assay Kit (396)
    Antibodies (165)
    Proteins (35)
    Research Biosimilar (141)
  • Expression system
    0 selected
    E. coli (20)
    Mammalian Cells (157)
  • Target
    0 selected
    Olokizumab (1)
    Nirsevimab (1)
    Ocaratuzumab (1)
    Natalizumab (2)
    Favezelimab (1)
    CTLA4 & PD1 (2)
    gC/Envelope glycoprotein C (1)
    Drozitumab (1)
    Simlukafusp Alfa (1)
    Eldelumab (1)
    Enfortumab (1)
    Sacituzumab (1)
    Denosumab (3)
    SARS-CoV-2 Neutralization Antibody (3)
    T3E (1)
    Tibulizumab (1)
    Emactuzumab (1)
    Imalumab (1)
    sCD14 (1)
    Zampilimab (1)
    TPP15 (1)
    Glembatumumab (1)
    Disitamab (1)
    CD274/PD-L1 & CD3E (1)
    Marstacimab (1)
    Omalizumab (2)
    Glycoprotein (5)
    Pasotuxizumab (1)
    Basiliximab (1)
    Apamistamab (1)
    M1R (5)
    Ranibizumab (3)
    S100A1 (1)
    RBD (Gamma) (1)
    CD79B (2)
    Letolizumab (1)
    Dupilumab (3)
    CD274/PD-L1 & CD137/TNFRSF9 (1)
    CD80/B7-1 (12)
    RBD (E484K) (1)
    Spike glycoprotein (RBD) (1)
    Tesidolumab (1)
    Sirukumab (1)
    Palivizumab (3)
    gC/UL44 (1)
    Lexatumumab (1)
    TRP-1 & CD3e (1)
    Calprotectin (S100A8/9) (2)
    Cetuximab (3)
    Ipilimumab (2)
    RBD (Omicron/BA.5) (3)
    T-cell surface antigen T3/Leu-4 epsilon chain (1)
    CD274/PD-L1 (59)
    Golimumab (3)
    Vunakizumab (1)
    Tosatoxumab (1)
    F/Fusion glycoprotein F0 (5)
    TPP17 (1)
    Lupartumab (1)
    Balstilimab (1)
    Pertuzumab (3)
    CD274/PD-L1 & CD47/MER6 (1)
    Dilpacimab (1)
    DCT (1)
    RBD (6)
    Anifrolumab (1)
    M/Matrix protein (2)
    Rosopatamab (2)
    PMEL17/ME20M (4)
    Camidanlumab (1)
    Frovocimab (1)
    Varisacumab (1)
    HLA-A2-peptide (TDQVPFSV) Complex (1)
    S100A4 (2)
    Astegolimab (1)
    CD274/PD-L1 & CD152/CTLA4 (1)
    Alacizumab (1)
    CD137/4-1BB & CD274/PD-L1 & ROR1 & CD3 (1)
    H3L (3)
    RBD (Kappa) (1)
    Afasevikumab (1)
    Ziltivekimab (1)
    Suptavumab (1)
    Carlumab (1)
    MLANA (1)
    Romiplostim (2)
    Indatuximab (1)
    gD/US6 (1)
    Tigatuzumab (1)
    CD278/ICOS (1)
    Lenzilumab (1)
    Ianalumab (1)
    Semorinemab (1)
    Etanercept (3)
    Tremelimumab (1)
    NP/Nucleoprotein (3)
    T-cell surface glycoprotein CD3 epsilon chain (1)
    SOX10 (2)
    Cixutumumab (1)
    Andecaliximab (1)
    CD366/HAVCR2/TIM-3 (1)
    RBD (Omicron/BA.4/BA.5) (1)
    Vofatamab (1)
    TPP47 (1)
    S100A5 (4)
    Cetrelimab (1)
    Trastuzumab (2)
    CD274/PD-L1 & CD134/OX40 (1)
    Navicixizumab (1)
    Obinutuzumab (2)
    RBD (Delta) (3)
    Tirzepatide (2)
    S100A2 (1)
    Tarextumab (1)
    Daclizumab (1)
    Lodelcizumab (1)
    Emibetuzumab (1)
    HLA-A2-peptide (ITDQVPFSV) Complex (4)
    Ivuxolimab (1)
    Itolizumab (1)
    CD274/PD-L1 & TGFBR2 (1)
    Iscalimab (1)
    CD279/PD-1 & CD152/CTLA4 (4)
    Ramucirumab (1)
    Bimagrumab (1)
    Fluorescein & CD274/PD-L1 (1)
    E8L (5)
    Crizanlizumab (1)
    RBD (Delta Plus) (1)
    EPO/Erythropoietin (1)
    Tanezumab (1)
    Bimekizumab (1)
    Aflibercept (1)
    US8/gE (1)
    Amatuximab (1)
    Namilumab (1)
    TRP-1 & CD47/MER6 (1)
    Tilavonemab (1)
    Zalifrelimab (1)
    TFF3 (1)
    RBD (Omicron/JN.1) (1)
    Infliximab (2)
    Tiragolumab (2)
    Dalotuzumab (1)
    Obiltoxaximab (1)
    Mazdutide (2)
    G/Major surface glycoprotein G (1)
    Depatuxizumab (1)
    Nivolumab (3)
    Zanidatamab (1)
    Atezolizumab (3)
    Afutuzumab (1)
    Spike glycoprotein (9)
    Icrucumab (1)
    CD274/PD-L1/B7-H1 (1)
    GP/Envelope glycoprotein (4)
    Urelumab (1)
    HLA-A2-peptide (YLEPGPVT) Complex (4)
    Pogalizumab (1)
    Belantamab (1)
    CD223/LAG3 & CD152/CTLA4 (1)
    CD274/PD-L1 & SLT-Ia (1)
    Utomilumab (1)
    Ibalizumab (1)
    Tezepelumab (1)
    Tocilizumab (3)
    LAG3 & PD-1 (1)
    A35R (5)
    Inclacumab (1)
    Semaglutide (2)
    Ixekizumab (1)
    Cergutuzumab (1)
    Suvizumab (1)
    Lorvotuzumab (1)
    Lintuzumab (1)
    Spike glycoprotein E2 (2)
    Anetumab (1)
    CD175/Tn (8)
    Otilimab (1)
    TRP-1 & CD134/OX40 (1)
    Blosozumab (1)
    Zagotenemab (1)
    Sarilumab (2)
    RBD (Omicron/KP.2) (1)
    Figitumumab (1)
    TIGIT & CD274/PD-L1 (1)
    Farletuzumab (1)
    Elotuzumab (1)
    Oxelumab (1)
    N/Nucleoprotein (1)
    Losatuxizumab (1)
    Pembrolizumab (3)
    CD274/PD-L1 & CD28 (1)
    Avelumab (3)
    Epcoritamab (1)
    Spike Protein (Trimer) (2)
    gG/US4 (2)
    S100A8 (1)
    Daratumumab (3)
    CD47/MER6 & CD274/PD-L1 (2)
    HLA-A2-peptide (KTWGQYWQV) Complex (2)
    Tavolimab (1)
    CD274/PD-L1 & VEGFA (1)
    Cusatuzumab (1)
    TYRP1 (1)
    CD19 & PD-L1 & CD3E & CD137 (1)
    Varlilumab (1)
    CD366/TIM-3 (24)
    Teclistamab (1)
    Ascrinvacumab (1)
    CD274/PD-L1 & CD28 & CD152/CTLA4 (1)
    Ieramilimab (1)
    PDL1 & VEGF (1)
    gB/Envelope glycoprotein B (1)
    Benufutamab (1)
    Magrolimab (1)
    Tregalizumab (1)
    IL6 (1)
    Evolocumab (1)
    TDP2 (1)
    Adalimumab (3)
    BRAF/B-Raf (3)
    Remtolumab (1)
    Labetuzumab (1)
    Sotrovimab (1)
    Spike glycoprotein E1 (2)
    Faricimab (1)
    Romosozumab (1)
    Edrecolomab (1)
    CD340/ERBB2 (1)
    Canakinumab (1)
    CD152/CTLA4 & CD274/PD-L1 (1)
    Enoblituzumab (1)
    Ganitumab (1)
    Gremubamab (1)
    Mirvetuximab (1)
    RBD (WT) (1)
    Necitumumab (1)
    Sintilimab (1)
    Zenocutuzumab (1)
    Durvalumab (3)
    Glofitamab (1)
    NP/Nucleocapsid (5)
    CD366/TIM-3 & CD279/PD-1 (2)
    CD152/CTLA4 & CD279/PD-1 (1)
    Lirilumab (1)
    EGFR & CD3E & PD-L1 & 4-1BB (1)
    CD366/TIM-3 & CD274/PD-L1 (1)
    Vorsetuzumab (1)
    CD274/PD-L1 & CD279/PD-1 (1)
    Ibritumomab (1)
    Rituximab (1)
    gE/Envelope glycoprotein E (1)
    Zanolimumab (1)
    CD152/CTLA4 & CD134/OX40 (1)
    Elezanumab (1)
    Lacnotuzumab (1)
    Eculizumab (3)
    Olaratumab (1)
    Alirocumab (1)
    CD3E (1)
    Secukinumab (2)
    VSIR/VISTA & CD274/PD-L1 (1)
    Foravirumab (1)
    Tisotumab (1)
    Casirivimab (1)
    Oleclumab (1)
    dsRNA (1)
    Nesvacumab (1)
    Ontamalimab (1)
    Milatuzumab (1)
    Befovacimab (1)
    Ustekinumab (3)
    IL1RL1/ST2 (1)
    Gevokizumab (1)
    Mirzotamab (1)
    Teprotumumab (1)
    Bevacizumab (3)
    RBD (Alpha) (1)
    Panitumumab (3)
    Tislelizumab (1)
    S100B (6)
    Pacmilimab (1)
    CD80/B7-1 & CD86/B7-2 (2)
    Ifabotuzumab (1)
    FLT1/VEGFR1 & CD274/PD-L1 (1)
    CD137/4-1BB & CD274/PD-L1 (3)
    CD223/LAG3 (30)
    Talacotuzumab (1)
    CD274/PD-L1 & TGFBR2/TGFR-2 (1)
    CD223/LAG3 & CD279/PD-1 (4)
    Cinpanemab (1)
    Clazakizumab (1)
    Mosunetuzumab (1)
    Mavezelimab (1)
    gD/Envelope glycoprotein D (1)
    Conatumumab (1)
    Sibrotuzumab (1)
    Tovetumab (1)
    MITF (1)
    B6R/SL-159 (1)
    gp100 peptide-HLA Complex (1)
    Guselkumab (2)
    Certolizumab (2)
    Cabiralizumab (1)
    Rafivirumab (1)
    Imdevimab (1)
    CD117/KIT (18)
    ATP7B (1)
    Vanucizumab (1)
    CD279/PD-1 & CD274/PD-L1 (1)
    Mirikizumab (2)
    Concizumab (1)
    IDO1 (1)
    Rolinsatamab (1)
    dsDNA (1)
    Omburtamab (1)
    A29L (6)
    Brolucizumab (1)
    RBD (Beta) (1)
    Serclutamab (1)
    Toripalimab (1)
    CD152/CTLA4 (59)
    Codrituzumab (1)
    Meplazumab (1)
    CD86/B7-2 (15)
    Vibecotamab (1)
  • Species
    0 selected
    Homo sapiens (Human) (3)
    Dog (2)
    Mouse (16)
    Mus musculus (Mouse) (5)
    Human (156)
    Canis lupus familiaris (1)
    Canis lupus familiaris (Dog) (4)
    Tupaia chinensis (2)
    Felis catus (Cat) (4)
  • Applications
    0 selected
    FCM (84)
    SPR (3)
    in vivo (2)
    SDS-PAGE (35)
    GICA (2)
    Immunogen (35)
    IHC (32)
    IF (2)
    Bioactivity testing in progress (16)
    WB (69)
    Neutralization (2)
    ELISA (665)
    in vivo CTLA-4 neutralization (1)
    Bioactivity: FACS (139)
    in vivo intra-tumoral regulatory T cell depletion (1)
    Research in vivo (1)
    FACS (3)
    FuncS (17)
    Functional assay (142)
    IFA (4)
    Functional assay (3)
    Research in vivo (142)
  • Reactivity
    0 selected
    Tupaia chinensis (2)
    Homo sapiens (Human) (1)
    Human (109)
    Bovine (1)
    Rat (7)
    Monkey (3)
    B7-H1 / PD-L1 / CD274 (1)
    Mouse (35)
    Dog (8)
    Pig (1)
  • Host species
    0 selected
    Armenian Hamster (3)
    Humanized (34)
    Dog (2)
    Chimeric (5)
    Rat (6)
    Human (129)
    Rabbit (21)
    Mouse (98)
    Alpaca (5)
  • Clonality
    0 selected
    Monoclonal (285)
    Polyclonal (17)
  • Conjugate
    0 selected
    APC (1)
    Unconjugated (240)
    FITC (12)
    PerCP (16)
    PE (27)

Quick access

Contact Us

  • +86-27-65523339

  • info@abinscience.com

  • Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China

  • linkedin
  • Ins
  • youtube
  • youtube
Copyright © 2026 abinScience. All Rights Reserved. All Products are for Research Use Only